Business Wire

31. Voyager Enables Microgravity-Enabled Drug Discovery 1/22/2026

    Voyager Technologies announced a new contract with Space LiinTech to manifest a new payload to the International Space Station, advancing microgravity-enabled drug discovery.

32. Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas 1/20/2026

    Lantern Pharma Inc., a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas.

33. Organon Announces US Food And Drug Administration Approval Of Supplemental New Drug Application Extending Duration Of Use Of NEXPLANON (etonogestrel implant) 68 mg Radiopaque 1/16/2026

    Organon, a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant), which is indicated for use by women of reproductive potential to prevent pregnancy.

34. Tahoe Therapeutics And Alloy Therapeutics To Form Joint Venture And Develop First-In-Class Antibody-Drug Conjugates For Hard-To-Treat Cancers 1/13/2026

    Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers.

35. ConcertAI And Foundation Medicine Integrate Genomic And Clinical Data To Transform Translational Research And Efficient Drug Development 1/12/2026

    ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, and Foundation Medicine, a global, patient-focused precision medicine company, today announced a collaboration to combine their data assets for life sciences research. 

36. Summit Therapeutics Announces Clinical Trial Collaboration With GSK To Evaluate Ivonescimab In Combination With GSK's B7-H3 Antibody Drug Conjugate (ADC) 1/12/2026

    Summit Therapeutics Inc. today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).

37. Owkin Advances Frontier Model Development For Biological Artificial Super Intelligence, Accelerated By NVIDIA 1/12/2026

    Owkin, an AI company on a mission to solve the complexity of biology, today announced a collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model.

38. Lantern Pharma Announces Establishing An A.I. Center Of Excellence In India To Industrialize The RADR Platform And Accelerate Global Development Opportunities With Biopharma Companies 1/12/2026

    Lantern Pharma Inc., a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India.

39. insitro To Acquire CombinAbleAI To Complete Its Full Stack, Modality-Agnostic AI Platform For Drug Discovery And Design 1/12/2026

    insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML (Therapeutic Machine Learning) platform.

40. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.